Alto Neuroscience, Inc. (ANRO) stock
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
$29.54−1.08 (-3.53%)
Close on Nov 13, 2026Market cap $1.16BP/E –Yield –
Alto Neuroscience total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Alto Neuroscience's total debt was $13.48M at Sep 30, 2026. For fiscal 2025 it was $16.76M, up 63.4% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.76M | +63.4% |
| FY2024 | Dec 31, 2024 | $10.25M | +4.0% |
| FY2023 | Dec 31, 2023 | $9.86M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.48M | -33.6% |
| Q2 FY2026 | Jun 30, 2026 | $16.19M | -19.6% |
| Q1 FY2026 | Mar 31, 2026 | $16.02M | -19.7% |
| Q4 FY2025 | Dec 31, 2025 | $16.76M | +63.4% |
| Q3 FY2025 | Sep 30, 2025 | $20.31M | +100.0% |
| Q2 FY2025 | Jun 30, 2025 | $20.12M | +100.1% |
| Q1 FY2025 | Mar 31, 2025 | $19.94M | +100.2% |
| Q4 FY2024 | Dec 31, 2024 | $10.25M | +4.0% |
| Q3 FY2024 | Sep 30, 2024 | $10.16M | – |
| Q2 FY2024 | Jun 30, 2024 | $10.06M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.96M | – |
| Q4 FY2023 | Dec 31, 2023 | $9.86M | – |
See a number that looks wrong?